Aortic regurgitationDisease1 paperHumans1Trial sponsorsChristian Torp-Pedersen1 trialPhase 41,000 peopleLatestNov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 2Oct 2026: 03European Journal of Preventive CardiologyHumans·16 SepMetabolic obesity phenotypes and degenerative valvular heart disease: A cohort studyPopulationsASAIO JournalAnimals·16 SepExtending Normothermic Ex Situ Heart Preservation and Viability to 48 Hours via Protein Supplementation and Plasma ExchangeInterventionsJournal of Clinical MedicineReview·27 AugSodium-Glucose Cotransporter 2 Inhibitors in Valvular Heart Disease: Cardiovascular Benefit, Valve-Specific Effects, and Evidence Gaps-A Structured Narrative ReviewSGLT2 inhibitors
European Journal of Preventive CardiologyHumans·16 SepMetabolic obesity phenotypes and degenerative valvular heart disease: A cohort studyPopulations
ASAIO JournalAnimals·16 SepExtending Normothermic Ex Situ Heart Preservation and Viability to 48 Hours via Protein Supplementation and Plasma ExchangeInterventions
Journal of Clinical MedicineReview·27 AugSodium-Glucose Cotransporter 2 Inhibitors in Valvular Heart Disease: Cardiovascular Benefit, Valve-Specific Effects, and Evidence Gaps-A Structured Narrative ReviewSGLT2 inhibitors